Search - tctmd.com

Displaying 281 - 300 of 523

Sort: Relevancy | Date

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Shelley Wood

May 05, 2017

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Shelley Wood

May 03, 2017

News Industry News

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

May 02, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Daily News

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

Yael L. Maxwell

April 17, 2017

Presentation Fellows 2017

The Evolution of Drug-Eluting Stents

Presenter: Ajay J. Kirtane

April 07, 2017

News Industry News

REVA Receives CE Mark for Fantom

April 04, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

Presentation

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

February 13, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Daily News

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Michael O'Riordan

January 20, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Michael O'Riordan

December 14, 2016

Advertisement

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

The Evolution of Drug-Eluting Stents

REVA Receives CE Mark for Fantom

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content